Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE

BACKGROUND: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments. OBJECTIVE: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient su...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley, Kappos, Ludwig, Giovannoni, Gavin, Wiendl, Heinz, Selmaj, Krzysztof, Havrdová, Eva Kubala, Rose, John, Greenberg, Steven, Phillips, Glenn, Ma, Wei, Wang, Ping, Lima, Gabriel, Sabatella, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282160/
https://www.ncbi.nlm.nih.gov/pubmed/28984179
http://dx.doi.org/10.1177/1352458517735190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282160/
https://www.ncbi.nlm.nih.gov/pubmed/28984179
http://dx.doi.org/10.1177/1352458517735190

Ejemplares similares